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 Abstract
 The aim of this review is to indicate the current 
position on the role of thyroxine (T4) and fetal brain 
development with particular relevance to the human situation. 
Adequate maternal iodine nutrition and maternal circulating 
thyroxine (T4) concentrations are essential to ensure optimum 
T4 placental passage which in turn will ensure transport of 
T4 into fetal brain cells. These processes are discussed and 
the role of thyroid hormone transporters is considered. The 
emphasis on isolated maternal hypothyroxinaemia (IH) as 
an important factor affecting brain development is discussed 
from the animal experimental point of view as well as in 
the clinical setting. There is evidence of neurocognitive 
impairment as assessed by different modalities in children 
up to the age of 8 years and some suggestion of increased 
psychiatric disorder in older persons whose mothers had IH 
during gestation. Although international guidelines have not 
in general recommended thyroxine therapy for IH the recent 
demonstration of adverse obstetric outcomes in women with 
isolated maternal hypothyroxinaemia may warrant a revision 
of this strategy.
 Key words: isolated hypothyroxinaemia, 
pregnancy, neurocognitive, animal, obstetric, guidelines.
INTRODucTION
 The aim of this review is to indicate the current 
position on the role of thyroxine (T4) and fetal brain 
development with particular relevance to the human 
situation. Thyroid hormones have long been known to 
be involved in brain development. For example there is 
a wealth of animal and experimental data summarised 
by Grave in 1977 (1) and further reviewed (2, 3).
 The neurobiology of fetal brain development 
depends on many factors including the availability of 
thyroxine (T4) delivery to the fetal neurones (4) (Fig.1). 
While MCT8 facilitates thyroid hormone transport 
in to the neurone, OATP1C1 appears to be related to 
thyroid hormone transport into the astrocyte. At this 
stage it favours the transport of T4 more than T3 but 
as the deiodinase II is within the astrocyte this enables 
conversion to occur and then allows T3 to be transferred 
into the neurone. Other thyroid hormone transporters 
are probably regulating thyroid hormone transport in 
to the oligodendrocyte. These processes depend on 
maternal iodide supply, maternal T4 synthesis, maternal 
T4 placental transport and the conversion of T4 to T3 
in the fetus by the Type II deiodinase. There is also an 
important role for the thyroid hormone transporters in 
one or more of these processes (5). Thyroid hormone 
receptor development in brain occurs very early in 
gestation, certainly before the fetal thyroid begins to 
function which is around sixteen to eighteen weeks (6). 
In early gestation thyroid hormone effects on genes 
related to neurodevelopment, for example, myelin, can 
be recorded. The immune system also changes during 
pregnancy with a shift from the TH1 to TH2 cytokine 
profile and influence of TH17 (7). 
 Circulating thyroid hormones are transferred 
across the placenta in the first trimester they traverse 
both the syncytio and in cyto-trophoblast (Fig. 2). In 
the third trimester, only the syncytio-trophoblast is 
involved (8). The details of the precise roles of the 
thyroid hormone transporters illustrated in Figure 2 are 
not clear at present. 
 The temporal nature of various brain structures 
in development is illustrated in Figure 3. 
 Note that T4 levels are derived solely from 
the mother until mid-gestation when there is an 
increasing contribution from fetal thyroid. However, 
the contribution of maternal thyroid hormone, although 
reducing, is still necessary right up to the end of gestation. 
Also shown are the activities of the D3 deiodinase and 
the D2 deiodinase during gestation and in the post-natal 
period. It is noted that neuron proliferation and the 
onset of neuron migration to difference brain structures 
occurs during the first trimester and is sensitive to 
thyroid hormone. In animal experiments it is seen that 
many genes are affected by thyroid hormone in early 
gestation. However, it is not clear at the present time as 
to why specific genes respond to thyroid hormone only 
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in a temporally restricted manner. More information 
on the contribution of non-genomic actions of thyroid 
hormone is also required to better understand the 
developmental effect of the hormone on the brain. 
 The aim of this review is to emphasise the role 
of thyroxine (as opposed to TSH) as an important factor 
for fetal brain development. In the clinical situation, 
isolated hypothyroxinaemia (IH) occurs between 2.5 to 
10% depending on the definition of IH (9). This figure 
should be compared with the prevalence of thyroid 
antibodies (anti-thyroid peroxidase antibodies) at 10%. 
In contrast to the relatively high figures hyperthyroidism 
occurs in 0.2% and hypothyroidism (a high TSH) 
occurs in 2 to 2.5% with most of these being sub-
clinical, i.e. a high TSH with a normal free thyroxine 
(10). There are variable definitions of IH but it is noted 
that total T4 and free T4 are normally distributed 
(unlike TSH). The first indication of the importance of 
IH was made by Man et al. (11) who noticed a low 
circulating level of T4 (based on butanol extractable 
iodine measurements) below the trimester specific 
reference range. IH should be diagnosed when the 
TSH is within the gestational reference range. Thyroid 
antibodies may be positive or negative. During the last 
15 years there have been many studies which have 
included maternal hypothyroxinaemia defined as either 
the 10th , 5th or 2.5th lowest centile of FT
4
 (eg 12-14). 
Causes of IH include iodine deficiency, modification 
of the thyroxine affinity for TBG, placental five prime 
deiodinase type III activity and placental angiogenic 
factors (15). Recently IH has also been associated with 
P<0.05 is considered as significant
Figure 1. Transport of Thyroid Hormones into Neurones, 
Oligodendrocytes and Astrocytes. Shown is the transport of T4 and 
T3 from the  endothelial cells of the circulation via specific thyroid 
hormone transporters to different cell types. Note that different 
transport mechanisms are suggested depending on the neuronal 
cell type. Intracellular conversion of T4 to T3 via deiodinase 2 (Dio2) 
is essential in the astrocyte. BBB = Blood brain barrier; TH = Thyroid 
hormones (4).
Figure 2. Illustration of Placental transport of thyroid hormones in 
the first and third trimesters of pregnancy. ST = Syncitiotrophoblast; 
CT = Cytotrophoblast; T4 = Thyroxine; T3 = Triiodothyronine; rT3 = 
Reverse triiodothyronine; D2 = Deiodinase 2; D3 = Deiodinase 3; THTs 
= Thyroid Hormone Transporters (8).
Figure 3. Relation of thyroid hormone supply from maternal and 
fetal sources to brain structure development ion the human. T4 = 
Thyroxine; TSH = Thyroid Stimulating Hormone; TR= Thyroid hormone 
receptor; Apo Trs= unbound thyroid hormone receptors (3).
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iron deficiency (16); there is also the possibility of 
exposure to environmental contaminants or disruptors 
resulting in IH (17). 
 With respect to iodine, the WHO 
recommendation for iodine intake during pregnancy 
is 250 mcg per day (18). In Europe there is a high 
prevalence of mild iodine deficiency (19), especially 
in pregnancy (20) where it has deleterious effects on 
the neurocognitive performance of children (21). 
For example, a study in England has reported that 
there is a reduction in verbal IQ, total IQ and reading 
comprehension in children eight years old whose 
mothers were noted to have low urinary iodine in 
pregnancy (22). The general iodine situation in Europe 
has shown discrepancies between school children and 
pregnant women; a re-emerging of iodine deficiency 
in industrialised countries. While the iodine status in 
some countries is satisfactory many have an inadequate 
iodine status in pregnancy. It is estimated that about 
400 million people from twenty countries in Europe 
still have limited access to iodised salt (19). Although 
it is conceded that there is a necessity to lower salt 
consumption for cardiovascular reasons, this should 
not negate the strategy of introducing iodised salt as 
the concentration of iodine in the salt can be adjusted 
accordingly (23). When iodised salt is introduced 
there is a gratifying response in median urinary iodine 
and this was shown in Romania over ten years ago 
(24). However, in that country pregnant women are 
considered to be iodine deficient. The European Union 
has recognised this problem by the award of a grant 
(EUThyroid) from 2015 to 2018. The main aims of this 
study are to develop a European map of iodine status, to 
build the capacity of national iodine studies, to perform 
harmonised studies about iodine status and establish 
thyroglobulin as a biomarker for individual iodine 
status. In addition, it is hoped to provide evidence for 
the effectiveness of IDD prevention and monitoring 
programmes in Europe.
 As indicated above, first documentation of the 
adverse effect of maternal IH on the psychoneurological 
performance of progeny was shown by Man et al. (11) 
who demonstrated developmental deficits as early 
as eight months, but at the ages of four and seven, 
noted lower psychological scores compared to non- 
hypothyroxinaemic progeny. In six sibling sets the 
outcome was better when thyroxine therapy was given 
during pregnancy (25). However, scant attention was 
paid to this study because of the possibility of socio-
economic confounding factors as well as the relative 
inaccuracy of assessment of thyroid function at that 
time. The subject was re-awakened by the demonstration 
that psychomotor development in infancy appeared 
to be correlated with the maternal free thyroxine at 
twelve weeks gestation (12). Since then, examples 
of maternal IH and decrement in cognitive function 
have been obtained. For example, expressive language 
delay (26), poorer cognitive performance at five and 
a half years (27), lower mental scores in two year old 
infants of women with FT
4
 less than 5th centile (28), 
children aged five to six showing a poor performance 
in simple reaction time test (29) and children aged eight 
who scored 4.3 points lower in an IQ test compared 
to children from normal thyroxinaemic mothers (30). 
In addition there has been some evidence of maternal 
hypothyroxinaemia being associated with abnormal 
neuropsychiatric function. In six year old children there 
was a four times incidence of autistic symptoms (31). 
A Finnish nested control study showed an odds ratio 
of 1.75 (CI 1.22 to 2.5 p = 0.002) in relation to the 
development of schizophrenia (32). In eight year old 
children, symptoms of attention deficit hyperactivity 
disorder were more prevalent (33). This has been 
noted previously (34). In contrast there are some 
studies where maternal IH was not associated with any 
neurocognitive defect. There is no association between 
IH (free T4 at the fifth centile) and neurodevelopmental 
delay at nineteen months (35). However, this comprised 
a relatively small sample number (forty-three children). 
There was no association between mid-gestational free 
thyroxine and neurocognitive development at two years 
(36). However, as indicated above the influence of fetal 
thyroid production is already evident at mid-gestation. 
In a large number of children, recently reported, there 
was no association between maternal gestational free 
T4 and subsequent intellectual development at one year 
in four hundred and fifty-five children and at six to 
eight years in two hundred and eight-nine children (37).
EVIDENcE Of ADVERsE EffEcTs ON THE 
BRAIN Of IH IN ANIMAL MODELs
 Studies in mice and rats have shown changes in 
neuronal migration, changes in cytoarchitecture of the 
cortex and hippocampus, and reduction of cerebellar 
granular precursors (38, 39). In addition, there is an 
alteration in the neurogenesis of axon and dendrite 
formation as well as myelination synaptogenesis and 
neurotransmission. A recent study (40) has shown 
that gestational hypothyroxinaemia can affect the 
distribution of the glutaminergic synaptic proteins and 
neuronal plasticity through an astrocyte dependent 
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mechanism. This study involved co-culture model of 
astrocyte and hippocampal neurons to identify the sub-
unit of the NMDA glutamate receptor (GLUN1) and the 
synaptic adaptor protein CD3 squiggle. It emphasised 
the importance of neuron astrocyte cross-talk and 
deleterious effects of gestational hypothyroxinaemia. 
Changes in gene expression in the fetal cortex using 
an acute thyroid hormone injection model have 
been recently documented (41). In the mouse model 
identification of transcription factors mediating actions 
of thyroid hormones were documented. In addition, 
novel tier thyroid hormone response elements were 
identified in these genes in addition to specific micro 
RNAs affected by thyroid hormone treatment. It 
appears that a short period of low maternal thyroxine 
alters transcriptional response of the fetal cerebral 
cortex to exogenous T4 treatment. These data, if 
applicable to humans, may have important implications 
for the administration of thyroxine to pregnant women.
REcENT cLINIcAL sTuDIEs
 In an effort to evaluate the strategy of 
screening for thyroid function in early gestation with 
levothyroxine (T4) intervention therapy a prospective 
randomised controlled trial of T4 treatment versus 
no treatment in mothers with thyroid dysfunction 
was undertaken with the primary outcome being the 
assessment of IQ of the children tested between three 
and three and a half years (41). In this randomised 
trial, antenatal screening at a median gestation age of 
twelve weeks and treatment for hypothyroidism did 
not result in improved cognitive function in children 
at three years of age. Possible reasons for this negative 
outcome include the relatively late age of screening 
during gestation, as well as the non-specificity of the 
psychological tests. The results of a further randomised 
trial being undertaken in the USA are awaited with 
interest. Neuroimaging studies have shown some 
reduction in high hippocampal volume in children from 
mothers with inadequately treated hypothyroidism 
in pregnancy (42). Of more relevance to the current 
discussion is the demonstration (43) of an inverse 
association between FT
4
 and offspring IQ in a large 
data set. This was accompanied by the indication that 
total grey matter volume was also associated with mean 
child IQ at the age of six to eight as was cortex volume. 
Of interest is the fact that TSH was not as obviously 
associated with mean IQ as FT
4
. Furthermore, the data 
relating to free T4 indicates a potential deleterious effect 
of high normal or excess maternal FT
4
 in pregnancy 
on child IQ. Another factor which may influence the 
IQ is the activity of the deiodinase II which converts 
T4 to T3. There are data relating the deiodinase II 
gene polymorphism THR92ALAD2 (44). In the adult 
hypothyroid population receiving thyroxine there is 
some evidence that this polymorphism is associated 
with continuing symptomatology of hypothyroidism 
despite normal thyroid hormone levels, leading to a 
preference for combination therapy in the treatment of 
hypothyroidism (45). Recent data from 3,043 children 
from the Avon Longitudinal Study of Parents and 
Children and 221 children from the CATS II study 
indicated that children homozygous for Thr92Ala and 
exposed to lower FT
4
 levels had increased odds of an 
IQ <85 (46). Meta-analysis of these cohorts revealed 
increased odds of an IQ <85 OR=2.69 (95%CI 1.46, 
4.89) p=0.002 for FT
4
 in the lowest quartile and 
homozygous for Thr92Ala and OR=7.19(95%CI 
2.36, 22.0) p=0.0005 for FT
4
 in the lowest 2.5% and 
homozygous for Thr92Ala (in preparation). 
DOEs IH AffEcT OBsTETRIc OuTcOMEs?
 Early studies showed not apparent adverse 
outcomes, but Pop had noticed an increase in breach 
and caesarean section associated with FT
4
 less than 
10th centile (47). An increase in pre-term labour and 
macrosomia has also been noted (48) in addition to 
another study indicating more fetal distress, small for 
gestational age and muscular skeletal malformations 
(35). An increase in premature delivery and larger 
fetal and infant head size has also been shown (49). 
Recently analysis of Welsh participants in the 
Controlled Antenatal Thyroid Study has indicated 
that a high TSH was associated with miscarriage or 
stillbirth after twelve weeks in the untreated women 
(OR = 5.46, 95% CI 1.66 – 17.9 p = 0.004) with no 
miscarriages occurring in treated women, In women 
with IH offspring of untreated women had lower 
birthweight, earlier delivery and were more likely to 
have an early Caesarean section than those who received 
levothyroxine (50). These data suggest correction of IH 
might improve obstetric outcomes although replication 
particularly in iodine sufficient areas are required.
 The consensus on whether to treat isolated 
hypothyroxinaemia is not clear. There is the opinion 
that the available evidence does not support treatment 
of the condition (52) Guidelines from the American 
Thyroid Association (53) and the United States 
Endocrine Society (53) broadly suggest that it probably 
should not be treated, although partial replacement 
Figure 1. Light microscopic micrograph of testis in control group.
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may be initiated at the discretion of the care giver. 
The European Thyroid Association Guidelines (54) 
suggested no benefit in terms of obstetric outcome 
but recommended considering treatment in the first 
trimester because of the neuropsychological reasons. 
It was not recommended for trimesters two and three. 
In view of the adverse obstetric outcomes of IH 
already discussed it may be suggested to treat IH when 
discovered at any time during gestation.
 In conclusion, maternal hypothyroxinaemia 
is associated with impaired neuropsychological 
impairment of the offspring. Animal data show adverse 
effects on brain structure and function. There are some 
associations with IH and adverse obstetric outcomes. 
There are no randomised controlled clinical trials which 
show the benefit of treatment and there are no studies 
of outcome or treatment of IH and thyroid antibodies 
together. It is suggested now that careful evaluation 
of trimester specific free thyroxine range should be 
always undertaken. In the first trimester IH less than 
a 2.5th together with thyroid antibody positivity should 
be treated. IH less than 2.5th possibly should be treated 
at the discretion of the care giver. 
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